Organovo to Present Clinical Data of FXR314 in Phase 2 MASH in an Oral Presentation at The Liver Meeting Sponsored by the American Association for the Study of Liver Diseases
13. November 2024 08:06 ET
|
Organovo, Inc.
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel...
3D Bioprinting Market Industry Trends and Global Forecasts, 2019, 2024 and 2035: Advancements in Biomaterials and AI Integration, & Partnerships and Collaborations Propel the $4 Billion Market
23. Oktober 2024 04:02 ET
|
Research and Markets
Dublin, Oct. 23, 2024 (GLOBE NEWSWIRE) -- The "3D Bioprinting Market Industry Trends and Global Forecasts to 2035: Distribution by Type of Component, Type of Consumable, Type of Technology, Type of...
3D Bioprinting Market valued at USD 1.41 billion in 2024 | ExactitudeConsultancy
16. September 2024 03:47 ET
|
Exactitude Consultancy
Luton, Bedfordshire, United Kingdom, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Exactitude Consultancy, the market research and consulting wing of Ameliorate Digital Consultancy Private Limited has...
Wound Skin Substitutes Market Global Analysis to 2030, Featuring Coloplast, Smith & Nephew, MTF Biologics, MiMedx, AlloSource, Organogenesis, RTI Surgical, LifeNet Health and Molecular Biologicals
10. Juni 2024 06:55 ET
|
Research and Markets
Dublin, June 10, 2024 (GLOBE NEWSWIRE) -- The "Wound Skin Substitutes Market - A Global and Regional Analysis: Focus on Region, Country-Level Analysis, and Competitive Landscape - Analysis and...
3D Bioprinting Market is Expected to Reach $2.4 billion | MarketsandMarkets™
04. Juni 2024 08:30 ET
|
MarketsandMarkets Research Pvt. Ltd.
Chicago, June 04, 2024 (GLOBE NEWSWIRE) -- 3D Bioprinting market in terms of revenue was estimated to be worth $1.3 billion in 2024 and is poised to reach $2.4 billion by 2029, growing at a CAGR of...
3D Bioprinting Market Global Forecast to 2030, Featuring EnvisionTEC, Organovo, Inventia Life Science, Poietis, Vivax Bio, Allevi, Cyfuse Biomedical, 3D Bioprinting Solutions & Cellink Global
30. Januar 2024 10:07 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "3D Bioprinting Market by Component, Material, Application, End User, Regional Outlook - Global Forecast up to 2030" report has been added to ...
3D-Printed Organs Market Projected to Reach USD 2.13 Billion by 2030 – New Research Highlights Trends, Technologies and Regional Growth
30. Januar 2024 07:36 ET
|
Research and Markets
Dublin, Jan. 30, 2024 (GLOBE NEWSWIRE) -- The "Global 3D-Printed Organs Market 2030 by Organ, Technology, Material, Application, End-user & Region - Partner & Customer Ecosystem Competitive...
Organovo Presents FXR314 3D Human Tissue Model Findings That Show Improved Epithelial Barrier Function and Fibrosis Reduction at Crohn’s and Colitis Congress
25. Januar 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq: ONVO), a clinical stage biotechnology company focused on developing FXR314 in inflammatory bowel disease (IBD),...
United Kingdom 3D Printing Market: Poised for Remarkable Growth by 2028 - Driven by Technological Advances and Increased Adoption in Health and Automotive Sectors
23. Januar 2024 22:28 ET
|
Research and Markets
Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "United Kingdom 3D Printing Market Size & Share Analysis - Growth Trends & Forecasts (2023 - 2028)" report has been added to ...
Organovo To Present FXR314 IBD 3D Model Findings at Upcoming Crohn’s and Colitis Congress
09. Januar 2024 08:05 ET
|
Organovo, Inc.
SAN DIEGO, Jan. 09, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (NASDAQ: ONVO), a clinical stage biotechnology company that is focused on developing FXR314 in inflammatory bowel disease (IBD),...